RESUMEN
These two Phase I, open-label, single-dose, randomized, crossoverstudies in 40 healthymale subjects investigated the pharmacokinetic and safety profiles of various formulations of the amprenavir prodrug GW433908 in the presence and absence of food compared with amprenavir capsules. GW433908 is a phosphate ester prodrug of the antiretroviral protease inhibitor amprenavir, with improved solubility over the parent molecule and a potential for reduced pill burden on current dosing regimens. The calcium salt of the prodrug, GW433908G, was selected for further investigation, as it appeared to offer the greatest potential for the development of new drug formulations. In the fasting state, (1) GW433908G tablet and suspension were bioequivalent in terms of both AUC and Cmax, and (2) GW433908G tablet and suspension were bioequivalent to amprenavir capsules for AUC; however, Cmax was lower with GW433908G. After a high-fat meal compared with fasting, (1) the bioavailability of GW433908G suspension was decreased by 20% and Cmax by 41%, and (2) for GW433908G tablets, there was no influence on AUC(12% lower Cmax). After a low-fat meal compared with fasting, (1) there was bioequivalence for GW433908G tablets, but (2) bioavailability was decreased by 23% for amprenavir capsules (Cmax was also lower, by 46%). Overall, for GW433908G and amprenavir capsules, food had a negligible influence on plasma concentration at 12 hours postdose (C12). Whether administered as tablets or suspension, GW433908G pharmacokinetics was only slightly affected by food. GW433908G tablets were well tolerated and delivered plasma amprenavir concentrations equivalent to the recommended therapeutic amprenavir dose but with fewer tablets. The possibility of a lower pill burden offered by GW433908 may be of clinical benefit in the treatment of HIV infection.
Asunto(s)
Organofosfatos/farmacocinética , Profármacos/farmacocinética , Sulfonamidas/farmacocinética , Adolescente , Adulto , Área Bajo la Curva , Cápsulas/administración & dosificación , Cápsulas/farmacocinética , Carbamatos , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Ayuno/fisiología , Interacciones Alimento-Droga , Furanos , Salud , Humanos , Masculino , Persona de Mediana Edad , Organofosfatos/administración & dosificación , Organofosfatos/efectos adversos , Organofosfatos/sangre , Profármacos/administración & dosificación , Profármacos/efectos adversos , Sulfonamidas/administración & dosificación , Sulfonamidas/efectos adversos , Sulfonamidas/sangre , Suspensiones/administración & dosificación , Suspensiones/farmacocinética , Comprimidos/administración & dosificación , Comprimidos/farmacocinéticaRESUMEN
The oral pharmacokinetics of cilomilast (Ariflo) were investigated in five separate studies in healthy volunteers. Cilomilast was rapidly absorbed, and pharmacokinetics were dose proportional after single and repeat dosing. The elimination half-life was 7 to 8 hours; accordingly, steady state was reached on the 3rd day of dosing. The degree of accumulation following repeat twice-daily dosing was predictable from the data following a single dose. Although systemic exposure (AUC) was, on average, 21% higher in elderly (65-84 years) compared with young subjects, values for Cmax and t(1/2) were similar, and no difference in tolerability was noted. Single and repeat doses of cilomilast up to and including 15 mg (dosed before or taken between meals) were well tolerated. Dosing with food reduced the rate of absorption without affecting total bioavailability. Hence, tolerability was optimal in the fed state; repeat doses up to and including 30 mg twice daily aftermeals were well tolerated following dose titration.
Asunto(s)
3',5'-AMP Cíclico Fosfodiesterasas/antagonistas & inhibidores , Broncodilatadores/farmacocinética , Inhibidores de Fosfodiesterasa/farmacocinética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Envejecimiento/metabolismo , Área Bajo la Curva , Broncodilatadores/administración & dosificación , Broncodilatadores/efectos adversos , Ácidos Carboxílicos , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4 , Ácidos Ciclohexanocarboxílicos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Interacciones Alimento-Droga , Humanos , Masculino , Persona de Mediana Edad , Nitrilos , Inhibidores de Fosfodiesterasa/administración & dosificación , Inhibidores de Fosfodiesterasa/efectos adversosRESUMEN
OBJECTIVE: To demonstrate a lack of effect of steady-state concentrations of cilomilast, a new oral phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease, on warfarin-induced anticoagulation. METHODS: This 28-day, randomized, double-blind, placebo-controlled, parallel-group study involved 36 healthy men. All volunteers received warfarin once daily on days 1 through 24 of the study. After a standard 5-mg loading dose on days 1 and 2, the warfarin dose was titrated between days 3 and 10 to achieve a stable prothrombin time, expressed as international normalized ratio (INR). Volunteers received either cilomilast 15 mg twice daily or placebo on days 18 through 24. The primary end point was the INR on day 24. RESULTS: On day 24, the mean +/- SEM INR in subjects receiving concurrent warfarin and cilomilast was 1.35 +/- 0.05, compared with 1.38 +/- 0.07 in those receiving concurrent warfarin and placebo. The point estimate (90% CI) for the difference in day 24 INR values between cilomilast and placebo (adjusted for baseline) was 0.02 (90% CI-0.13 to 0.17), which translates to an INR ratio of 1.02 (90% CI 0.91 to 0.13). The 90% confidence interval for the ratio of mean INR (cilomilast:placebo) on day 24 was completely contained within the 25% equivalence range, indicating a lack of interaction between warfarin and cilomilast. The adverse event profiles of warfarin/placebo and warfarin/cilomilast were similar and favorable. CONCLUSIONS: The pharmacodynamics of warfarin are unaffected by coadministration of cilomilast at steady-state concentrations in healthy volunteers.
Asunto(s)
Anticoagulantes/farmacología , Broncodilatadores/farmacología , Inhibidores de Fosfodiesterasa/farmacología , Warfarina/farmacología , Adulto , Broncodilatadores/efectos adversos , Ácidos Carboxílicos , Ácidos Ciclohexanocarboxílicos , Método Doble Ciego , Interacciones Farmacológicas , Humanos , Relación Normalizada Internacional , Masculino , Persona de Mediana Edad , Nitrilos , Inhibidores de Fosfodiesterasa/efectos adversosRESUMEN
Gemifloxacin is a novel fluoroquinolone, currently in development for the treatment of respiratory tract infections. This double-blind (with respect to gemifloxacin), randomized, crossover study investigated the possibility of pharmacokinetic interaction between gemifloxacin and theophylline. After a 4-8-day run-in phase to establish the dose of theophylline required to achieve a trough plasma concentration range of 8-15 mg/l, 15 healthy volunteers entered a randomized treatment phase. Volunteers then received oral theophylline, 300-400 mg twice daily, for 22 days. On days 5-11 and 16-22, they also received either placebo or gemifloxacin, 320 mg p.o. once daily, in a crossover fashion. Blood samples were collected up to 12 h after the morning dose of theophylline on days 11 and 22. Theophylline pharmacokinetics were not affected by the co-administration of gemifloxacin. The maximum plasma concentration (C(max)) for theophylline ranged from 8.12 to 17.71 mg/l and from 8. 79 to 16.35 mg/l during concomitant administration with gemifloxacin and placebo, respectively. The corresponding ranges of the area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration (AUC((0-12))) were 84.6-177.5 mg. h/l and 94.8-165.1 mg.h/l during gemifloxacin and placebo administration, respectively. The point estimates (90% confidence intervals) for dose-normalized AUC((0-12)) and C(max) (theophylline + gemifloxacin):(theophylline + placebo) were 0.99 (0.93, 1.05) and 1.02 (0.93, 1.11), respectively, which were entirely within the equivalence range (0.80, 1.25). The co-administration of gemifloxacin and theophylline was well tolerated, with no clinically significant changes seen in vital signs, 12-lead electrocardiogram readings or laboratory parameters. Adverse events were generally transient, mild to moderate in nature and similar during the gemifloxacin and placebo treatment periods. In conclusion, theophylline and gemifloxacin may be co-administered without any adjustment in theophylline dose.
Asunto(s)
Antiinfecciosos/farmacología , Fluoroquinolonas , Naftiridinas/farmacología , Teofilina/farmacocinética , Adolescente , Adulto , Antiinfecciosos/efectos adversos , Estudios Cruzados , Método Doble Ciego , Interacciones Farmacológicas , Femenino , Gemifloxacina , Humanos , Masculino , Persona de Mediana Edad , Naftiridinas/efectos adversos , Teofilina/efectos adversosRESUMEN
Gemifloxacin is a novel fluoroquinolone with a broad spectrum of activity. This double-blind, randomized, parallel-group study was designed to demonstrate the lack of effect of steady-state concentrations of gemifloxacin on the pharmacodynamic effects of warfarin. Healthy male subjects received loading doses of warfarin on days 1 and 2. The warfarin dose was freely titrated until day 10, with the aim of achieving a stable international normalized ratio (INR) for prothrombin time within the range 1.3-1.8 by day 14. On days 14-24 the dose of warfarin was fixed. On days 18-24, subjects also received 320 mg of gemifloxacin or matched placebo, once daily. Thirty-five subjects entered into and completed the co-administration phase of the study. The mean (standard deviation) baseline INR (mean of days 16-18) and INR for day 24 for gemifloxacin plus warfarin were 1.52 (0.12) and 1.46 (0.15), respectively. Corresponding values for placebo plus warfarin were 1. 46 (0.11) and 1.42 (0.17). The point estimate (90% confidence interval) for the difference in day 24 INR, adjusted for baseline, between gemifloxacin and placebo was 0.02 (-0.08, 0.12), which translates to an INR (relative to placebo least squares mean of 1.43) of 1.02 (0.95, 1.09). The 90% confidence interval for the difference in INR between the gemifloxacin and placebo groups was completely contained within the 25% equivalence range. There were no changes of clinical significance in vital signs, 12-lead electrocardiogram readings or laboratory parameters for any subject during the co-administration phase of the study, and no adverse experiences relating to coagulation were reported during this period. It is concluded that the pharmacodynamic effects of warfarin are not affected by gemifloxacin, and therefore both drugs can be co-administered without dosage adjustment.
Asunto(s)
Antiinfecciosos/farmacología , Anticoagulantes/farmacología , Fluoroquinolonas , Naftiridinas/farmacología , Warfarina/farmacología , Adolescente , Adulto , Antiinfecciosos/efectos adversos , Método Doble Ciego , Interacciones Farmacológicas , Gemifloxacina , Humanos , Masculino , Persona de Mediana Edad , Naftiridinas/efectos adversos , Warfarina/efectos adversosRESUMEN
BACKGROUND: Pantoprazole is a proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 system, and linear pharmacokinetics. The recommended oral dose for treatment of acid-related diseases is 40 mg. METHODS: Using a randomized, crossover study design we compared the ability of 40 mg oral and intravenous pantoprazole to elevate the intragastric pH in healthy volunteers (n = 20, 'per protocol'), during two treatment phases. The duration of each phase was 5 days. Pantoprazole 40 mg was administered once daily either as a tablet or as an intravenous injection. A 24 h pHmetry was used to record the intragastric pH on day 5 of each regimen; this was compared to the baseline curve obtained before each study period. The calculated 90% confidence intervals (90% CI) represent the mean difference in the intragastric pH, attained after intravenous or oral administration. The predefined equivalence range for the 90% CI was +/- 20% for the percentage time at which the gastric pH was at least pH 3 or 4 and +/- 1 unit for the median pH. RESULTS: Pantoprazole was well tolerated during both treatment phases. The mean of the 24 h median pH was 3.3 and 3.1 for the intravenous and oral treatments, respectively; the corresponding differences were 0.2 (90% CI: - 0.03 to 0.44). For the mean percentage time at which the pH was 3 or above, the respective calculated values were 57% and 51%, with a difference between the two administration routes of only 5.7% (90% CI: 1.8 to 9.6). At an intragastric pH of 4 or above, the mean percentage time was 420% and 38% following intravenous and oral treatment, respectively, with a difference between the treatment routes of only 4.4% (90% CI: 0.6 to 8.3). CONCLUSIONS: These results imply that the two formulations of pantoprazole can be assumed to be equipotent. Hence, the intravenous formulation of pantoprazole could be considered as an alternative route of administration.
Asunto(s)
Antiulcerosos/administración & dosificación , Bencimidazoles/administración & dosificación , Bencimidazoles/farmacología , Ácido Gástrico/metabolismo , Sulfóxidos/administración & dosificación , Sulfóxidos/farmacología , 2-Piridinilmetilsulfinilbencimidazoles , Administración Oral , Adulto , Antiulcerosos/farmacología , Estudios Cruzados , Mucosa Gástrica/metabolismo , Humanos , Concentración de Iones de Hidrógeno , Inyecciones Intravenosas , Masculino , Omeprazol/análogos & derivados , PantoprazolRESUMEN
OBJECTIVE: Voglibose is a new and potent inhibitor of alpha-glucosidases used for treatment of diabetes mellitus. It increases gastro-intestinal motility and could thus affect absorption of other concurrently administered antidiabetic drugs. The aim of this study was to investigate whether or not voglibose modifies the pharmacokinetics of glibenclamide, a widely used oral antidiabetic, and the glibenclamide-induced decrease in fasting serum glucose. METHODS: Twelve healthy male subjects were included in this double-blind cross-over study and received a single 1.75-mg dose of glibenclamide on the 8th day of continuous administration of either placebo (reference) or voglibose 5 mg t.i.d. (test). Blood samples were taken to determine the pharmacokinetic characteristics of glibenclamide and the test/reference ratios were evaluated according to bioequivalence criteria. Additional blood samples were taken to measure serum glucose on the same day. RESULTS: The concentration-time course of glibenclamide under concomitant voglibose administration was similar to that under placebo. The equivalence ratio (test/reference) for the pharmacokinetic characteristics AUCnorm was 1.03 (geometric mean; 0.95-1.11, 90% confidence interval) and Cmax.norm 1.01 (0.94-1.08). The parameters were within the accepted range of 0.8-1.25 (AUC) or 0.7-1.43 (Cmax), thus fulfilling equivalence criteria and indicating no effect of voglibose on glibenclamide kinetics. The glibenclamide-induced decrease in fasting serum glucose concentration was similarly independent of placebo or voglibose co-administration. CONCLUSIONS: Voglibose did not interact with glibenclamide on a pharmacokinetic level. Concomitant treatment was well tolerated and has been proven to be safe for further clinical use.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Gliburida/farmacocinética , Inhibidores de Glicósido Hidrolasas , Hipoglucemiantes/farmacocinética , Inositol/análogos & derivados , Adulto , Área Bajo la Curva , Glucemia/efectos de los fármacos , Estudios Cruzados , Método Doble Ciego , Interacciones Farmacológicas , Gliburida/sangre , Humanos , Hipoglucemiantes/sangre , Inositol/farmacología , MasculinoRESUMEN
OBJECTIVE: Voglibose is a new and potent inhibitor of alpha-glucosidases and is used for the treatment of diabetes mellitus. Since voglibose increases gastrointestinal motility and could thus affect absorption of concomitantly administered drugs, it was investigated whether or not voglibose modifies the pharmacodynamics and pharmacokinetics of warfarin, an oral anticoagulant frequently used in cardiovascular disorders likely to arise in diabetic patients. METHODS: Twelve healthy male subjects were given individually adjusted doses of warfarin to reduce prothrombin time (Quick's method) to a value of about 30-40% of the normal range within the first 8 days. Then, the individuals maintenance dose, given in the morning, was maintained until day 15. On study days 11-15, voglibose was co-administered per os in a dose of 5 mg t.i.d. The prothrombin time was determined on days 10 and 11 (reference) and on days 15 and 16 (test), and the steady-state pharmacokinetic characteristics of the warfarin enantiomers were determined on days 10 (reference) and 15 (test). The ratios test/reference were evaluated according to bioequivalence criteria. RESULTS: The equivalence ratio (test reference) for the pharmacodynamic parameter prothrombin time was 0.97 and for the pharmacokinetic characteristics AUC0-24 h.t.ss: S-(-)-warfarin, 1.05; R-(+)-warfarin, 1.01; and Cmax.ss: S-(-)-warfarin, 1.08; R-(+)-warfarin, 1.04. All parameters were within the predetermined accepted range of 0.7-1.43 (pharmacodynamics) or 0.8-1.25 (pharmacokinetics), thus fulfilling equivalence criteria. CONCLUSIONS: Voglibose modified neither the pharmacodynamics nor the pharmacokinetics of warfarin under steady-state conditions. Concomitant treatment was well tolerated and has been proven to be safe for further clinical use.
Asunto(s)
Anticoagulantes/farmacología , Inhibidores Enzimáticos/farmacología , Inhibidores de Glicósido Hidrolasas , Inositol/análogos & derivados , Tiempo de Protrombina , Warfarina/farmacología , Warfarina/farmacocinética , Adulto , Anticoagulantes/farmacocinética , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Interacciones Farmacológicas , Femenino , Humanos , Inositol/farmacología , Masculino , Valores de ReferenciaRESUMEN
AIMS: Concomitant administration of magnesium hydroxide may affect the rate or extent of absorption of non-steroidal anti-inflammatory drugs. In order to find out whether or not buffering modifies the pharmacokinetics of ketoprofen, plasma concentration-time courses resulting from oral administration of unbuffered formulations were compared with those of buffered formulations. METHODS: Two groups of 12 healthy and young male subjects were included in two randomized cross-over studies and received single oral doses of ketoprofen 12.5 or 25 mg, respectively, given as tablets which were either unbuffered or buffered with magnesium hydroxide/citrate. Ketoprofen enantiomers in plasma were determined by h.p. l.c. up to 24 h post-dose. RESULTS: Maximum plasma concentrations (Cmax) of both the (R)- and (S)-enantiomer, observed after administration of the buffered formulations (12.5 and 25 mg), were higher compared with the unbuffered tablets by about 50-80%. The area under concentration-time data (AUC) was unaffected, and, hence, Cmax/AUC was increased by buffering. Time to Cmax (tmax) and mean residence time (MRT) tended to be or was shortened by buffering. CONCLUSIONS: It is concluded that buffering of two ketoprofen formulations with magnesium hydroxide/citrate enhanced the concentration maximum by increasing the rate of absorption and leaving AUC unaffected.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Cetoprofeno/farmacocinética , Adulto , Antiinflamatorios no Esteroideos/química , Área Bajo la Curva , Tampones (Química) , Cromatografía Líquida de Alta Presión , Citratos/farmacología , Estudios Cruzados , Fármacos Gastrointestinales/farmacología , Humanos , Cetoprofeno/química , Hidróxido de Magnesio/farmacología , Masculino , EstereoisomerismoRESUMEN
OBJECTIVE: Pantoprazole is a selective proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 enzymes in man. Due to the clinical importance of an interaction with anticoagulants, this study was carried out to investigate the possible influence of pantoprazole on the pharmacodynamics and pharmacokinetics of phenprocoumon. METHODS: Sixteen healthy male subjects were given individually adjusted doses of phenprocoumon to reduce prothrombin time ratio (Quick method) to about 30-40% of normal within the first 5-9 days and to maintain this level. The individual maintenance doses remained unaltered from day 9 on and were administered until day 15. Additionally, on study days 11-15, pantoprazole 40 mg was given per once daily. As a pharmacodynamic parameter, the prothrombin time ratio was determined on days 9 and 10 (reference value) and on days 14 and 15 (test value), and the ratio test/reference was evaluated according to equivalence criteria. RESULTS: The equivalence ratio (test/reference) for prothrombin time ratio was 1.02 (90% confidence interval 0.95-1.09), thus fulfilling predetermined bioequivalence criteria (0.70-1.43). The pharmacokinetic characteristics AUC0-24h and Cmax of S(-)- and R(+)-phenprocoumon were also investigated using equivalence criteria. Equivalence ratios and confidence limits of AUC0-24h and of Cmax of S(-)-phenprocoumon (0.93, 0.87-1.00 for AUC0-24h; 0.95, 0.88-1.03 for Cmax) and of R(+)-phenprocoumon (0.89, 0.82-0.96; 0.9, 0.83-0.98) were within the accepted range of 0.8-1.25. CONCLUSION: Pantoprazole does not interact with the anticoagulant phenprocoumon on a pharmacodynamic or pharmacokinetic level. Concomitant treatment was well tolerated.
Asunto(s)
Anticoagulantes/farmacocinética , Bencimidazoles/farmacología , Fenprocumón/farmacocinética , Inhibidores de la Bomba de Protones , Sulfóxidos/farmacología , 2-Piridinilmetilsulfinilbencimidazoles , Adulto , Sistema Enzimático del Citocromo P-450/fisiología , Interacciones Farmacológicas , Humanos , Masculino , Omeprazol/análogos & derivados , Pantoprazol , Fenprocumón/farmacología , EstereoisomerismoRESUMEN
Lansoprazole is a potent proton pump inhibitor and blocks gastric acid secretion. The potency of many antibiotics in eradicating Helicobacter pylori may be considerably enhanced by increasing the intragastric pH due to a twice-daily coadministration of proton pump inhibitors. This double-blind crossover study was designed to compare the effect on intragastric pH of four dose regimens of lansoprazole (30 mg o.a.d., 30 mg b.i.d., 45 mg b.i.d., 60 mg b.i.d.) after 5 days of treatment and to investigate whether an increment of lansoprazole dose level leads to a more pronounced effect. Omeprazole 20 mg b.i.d. was administered as a reference drug. The study was carried out in 20 healthy male subjects. Intragastric pH was recorded by a nasogastric probe over 24 h. All dose regimens of lansoprazole were well tolerated and no unexpected drug-related adverse events were observed. The lowest lansoprazole dose level, 30 mg o.a.d. already increased intragastric pH considerably. This effect was even enhanced by increase of the lansoprazole dose as assessed by mean pH as well as percentage of time spent above different pH values. The increase in effect with lansoprazole dose increment from 30 mg b.i.d. to 60 mg b.i.d. was only very small. The time spent at pH values above or equal to 3 after b.i.d. administration was slightly higher with all lansoprazole dose levels compared to omeprazole. The time spent at intragastric pH values above or equal to 5 after b.i.d. oral administration of 30 mg, 45 mg and 60 mg lansoprazole was comparable to that observed after b.i.d. oral administration of 20 mg omeprazole, so that it may be recommended to use lansoprazole 30 mg b.i.d. as a treatment equivalent to omeprazole 20 mg b.i.d. for eradication of Helicobacter pylori in combination with antibiotics.
Asunto(s)
Antiulcerosos/farmacología , Inhibidores Enzimáticos/farmacología , Ácido Gástrico/metabolismo , Omeprazol/análogos & derivados , Omeprazol/farmacología , 2-Piridinilmetilsulfinilbencimidazoles , Adolescente , Adulto , Antiulcerosos/administración & dosificación , Estudios Cruzados , Método Doble Ciego , Inhibidores Enzimáticos/administración & dosificación , Humanos , Concentración de Iones de Hidrógeno/efectos de los fármacos , Lansoprazol , Masculino , Persona de Mediana Edad , Omeprazol/administración & dosificación , Inhibidores de la Bomba de ProtonesRESUMEN
A promising new design aimed at testing bioequivalence of levo-thyroxine preparations in male euthyreotic volunteers was investigated in a pilot study. Healthy volunteers received a single oral dose of levo-thyroxine (200 micrograms of the same formulation, 2 tablets of 100 micrograms each) in 4 subsequent periods with washout times of 1 week between administrations. Consistent increases in serum levo-thyroxine concentrations were observed after intake of each dose. The number of volunteers included, in our case 12, was sufficient to state bioequivalence of the medication given in 4 subsequent periods as assessed by area under data after subtraction of area under basal levo-thyroxine concentrations determined on the day before drug administration, and allowed an estimate of the minimum number required for future studies. Furthermore, combination of individual values from different periods of identical treatment may lead to a reduction of minimum sample size. The design tested could also be used as a crossover design to obtain a reliable parameter related to relative levo-thyroxine bioavailability and is a promising alternative to another model where bioavailability can be tested in athyreotic patients. The medication was well tolerated and no adverse events related to medication were found. Safety parameters failed to reveal any marked change during the 4 study periods.
Asunto(s)
Tiroxina/farmacocinética , Administración Oral , Adulto , Análisis de Varianza , Disponibilidad Biológica , Esquema de Medicación , Alemania , Humanos , Masculino , Proyectos Piloto , Radioinmunoensayo , Valores de Referencia , Tiroxina/administración & dosificación , Tiroxina/sangreRESUMEN
The pharmacokinetics and comparative bioavailability of oxyfedrine after single-dose oral administration of oxyfedrine*HCl tablets in comparison to an equimolar aqueous solution of oxyfedrine*HCl were investigated in 12 healthy male subjects. Six of them received 96 mg DL-oxyfedrine*HCl as tablets and solution and the remaining 6 subjects received 16 mg DL-oxyfedrine*HCl as tablets and solution in a randomized cross-over design. For evaluation of the relative bioavailability of the tablet formulation, the main metabolite norephedrine (expressed as hydrochloride) was analyzed in plasma for all 12 subjects. Furthermore, for determination of the parent drug, samples of whole blood were analyzed for DL-oxyfedrine*HCl. Relevant concentrations of the parent drug were found only in the high dosage group. There was no evidence of dose-linearity referring to AUC and Cmax of norephedrine between 16-mg and 96-mg doses of DL-oxyfedrine*HCl. The relative bioavailability of the tablet formulation after administration of 16 mg DL-oxyfedrine*HCl, based on the metabolite norephedrine*HCl was for AUC: 85.37% within a 90% confidence interval of 69.29-105.17% and for Cmax: 78.79% within a 90% confidence interval of 59.19-104.90%. The figures for the 96 mg dose strength were: AUC: 107.85% (90.06-129.15%) and for Cmax: 74.74% (62.48-89.42%).
Asunto(s)
Oxifedrina/farmacocinética , Administración Oral , Adolescente , Adulto , Análisis de Varianza , Disponibilidad Biológica , Estudios Cruzados , Humanos , Masculino , Persona de Mediana Edad , Norepinefrina/sangre , Oxifedrina/sangre , Oxifedrina/metabolismo , Soluciones , ComprimidosRESUMEN
Effects of indomethacin, N omega-nitro-L-arginine (NNA) and naloxone, and of pretreatment with cyclophosphamide (CY), on the interleukin (IL)-1 beta induced inhibition of exocytotic noradrenaline release were investigated in the isolated, vascularly perfused spleen of the rat. Neurotransmitter release was evoked by perivascular electrical stimulation (4 Hz) and the overflow of endogenous noradrenaline was determined by HPLC with electrochemical detection. Perfusion of the spleen with Tyrode's solution containing IL-1 beta (100 pg/ml) for 90 min caused an inhibition of the stimulation-evoked noradrenaline overflow which persisted for at least 20 min after washout of the IL. The evoked overflow was reduced in the presence of NNA 30 mumol/l, but remained unaffected by indomethacin 3 mumol/l, naloxone 0.1 mumol/l or treatment of the rats with CY (250 mg/kg). The opioid agonist etorphine 10 mumol/l inhibited the evoked overflow of noradrenaline and this effect was prevented by naloxone 0.1 mumol/l. The inhibition of evoked overflow by IL-1 beta was not affected by indomethacin but was reduced or even prevented in the presence of NNA or naloxone, or after lymphocyte depletion of spleens by CY. The results are compatible with the idea that in the rat spleen exocytotic noradrenaline release is accompanied by a concomitant secretion of a nitric oxide (NO)-like compound which, in turn, reinforces noradrenaline release, and that the release can be inhibited via prejunctional opioid receptors. The IL-1 beta induced inhibition of evoked release appears to be a complex process which involves as one of many steps a decrease of the facilitatory NO-like compound and the release of endogenous opioids probably from spleen lymphocytes.
Asunto(s)
Interleucina-1/farmacología , Linfocitos/metabolismo , Óxido Nítrico/metabolismo , Norepinefrina/metabolismo , Receptores Opioides/metabolismo , Bazo/metabolismo , Animales , Arginina/análogos & derivados , Arginina/farmacología , Peso Corporal/efectos de los fármacos , Ciclofosfamida/farmacología , Estimulación Eléctrica , Técnicas In Vitro , Indometacina/farmacología , Linfocitos/efectos de los fármacos , Masculino , Naloxona/farmacología , Óxido Nítrico/antagonistas & inhibidores , Nitroarginina , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Wistar , Receptores Opioides/efectos de los fármacos , Bazo/citología , Bazo/efectos de los fármacosRESUMEN
The alpha-glucosidase inhibitor voglibose (AO-128) was designed to prevent rapid postprandial blood glucose rises in non-insulin-dependent diabetics. We analyzed its effect on the entero-insular axis in 72 healthy volunteers in a double-blind study design before, after the 1st dose, and on the 7th day of a 7-day treatment protocol (3 daily loads). Six parallel groups of 12 volunteers received voglibose (0.5, 1.0, 2.0, or 5.0 mg) or placebo (two groups). Blood was drawn at regular intervals up to 180 min after a standardized breakfast to analyze the levels of glucose, insulin, C peptide, gastric inhibitory polypeptide, and glucagon-like peptide 1 (GLP-1). As expected, after ingestion of voglibose, slight to moderate gastro-intestinal discomfort but no severe side-effects were reported. In a dose-dependent manner, voglibose significantly reduced postprandial increases of blood glucose, insulin, and C peptide. At the lower loads (0.5 and 1 mg voglibose three times daily), these effects were more pronounced after 7 days. The postprandial increase of gastric inhibitory polypeptide was already reduced after the first load of 2 and 5 mg voglibose. In comparison to the placebo group, this inhibition became also significant for the lower loads after 7 days. Interestingly, GLP-1, originating from the lower intestines, was increasingly released under voglibose treatment. The first administration of 1 mg voglibose enhanced GLP-1 secretion > 80% above controls. Treatment with 1 mg voglibose three times daily over 7 days revealed a maximal mobilizing effect on endogenous GLP-1 (> 90% above controls) which was not further increased by 2- or 5-mg loads. We conclude that voglibose treatment effectively inhibits intestinal disaccharidases and thereby mobilizes the endogenous pool of insulinotropic GLP-1.
Asunto(s)
Ciclohexanoles/farmacología , Glucagón/sangre , Inhibidores de Glicósido Hidrolasas , Fragmentos de Péptidos/sangre , Precursores de Proteínas/sangre , Adolescente , Adulto , Glucemia/metabolismo , Péptido C/sangre , Ciclohexanoles/efectos adversos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Inhibidores Enzimáticos/farmacología , Polipéptido Inhibidor Gástrico/sangre , Péptido 1 Similar al Glucagón , Humanos , Insulina/sangre , MasculinoRESUMEN
This investigation was aimed at the determination of the absolute bioavailability of theophylline and quinine after single oral dose administration of Limptar tablets or Limptar N tablets with reference to intravenous administration of Euphyllin 0.48 short infusion and Chininum dihydrochloricum Buchler solution for injection. The study design was characterized as single dose, three-factorial, four-treatment, four-period Latin square design (factor A: period, factor B: treatment, factor C: sequence). The target parameters were AUCnorm, AUC0-infinity, ABA, and secondary parameters Cmax, tmax, t1/2 lambda z, MRT, HVD. The study was carried out on 12 healthy nonsmoking male volunteers between 24 and 42 years of age and confined to a ward for 4 study days (but not during the remaining days of washout phases which lasted 1 week). The treatments (not blinded) were as follows: b1, Chininum dihydrochloricum Buchler solution for injection, infusion of 163.3 mg quinine; b2, Euphyllin 0.48, short infusion of 168.6 mg theophylline; b3, Limptar tablets, 1 tablet containing 215.5 mg quinine and 167.2 mg theophylline; b4, Limptar N tablets, 1 tablet containing 165.75 mg quinine. A validated HPLC-UV method was used to determine plasma concentrations of drugs. The absolute bioavailability of theophylline and quinine from the two formulations Limptar and Limptar N was nearly complete (90% on the average). Administration of Limptar N tablets resulted in quinine concentrations which were higher and reached maximum faster as compared to administration of Limptar. Average quinine concentrations observed 8.0 h p.a. of Limptar exceeded those seen with Limptar N. Accordingly, this was as well reflected by a doubling of half duration time after Limptar compared to Limptar N. With respect to the safety parameters such as hemodynamics, ECG, hematology, clinical chemistry and urinalysis, there were no clinically relevant findings. All adverse events observed or reported during the study (mainly blurred vision and headache) were mildly pronounced, rated as possibly drug-related or unrelated to the study drugs, and disappeared spontaneously within the confinement period in the ward. In conclusion, the medications tested were well tolerated. No major differences in tolerability of quinine or theophylline given alone or in combination were observed. The difference in pharmacokinetic behavior of quinine in the two oral formulations may result from differences in pharmaceutical characteristics of the formulations.
Asunto(s)
Quinina/farmacocinética , Teofilina/farmacocinética , Administración Oral , Adulto , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Estudios Cruzados , Semivida , Humanos , Infusiones Intravenosas , Masculino , Quinina/administración & dosificación , Quinina/efectos adversos , Espectrofotometría Ultravioleta , Comprimidos , Teofilina/administración & dosificación , Teofilina/efectos adversosRESUMEN
The aim of the present study was to investigate whether or not release of endogenous mast cell mediators modulates exocytotic noradrenaline overflow. Therefore, we perfused rat isolated hearts with the right sympathetic innervation intact and investigated the effect of mast cell degranulation on the efflux of noradrenaline. Compound 48/80 (48/80), a mast cell degranulating agent, caused a large release of histamine and serotonin and a facilitation of evoked noradrenaline overflow. When 48/80 was introduced into the perfusion medium 4 min before sympathetic nerve stimulation (SNS), evoked noradrenaline overflow was increased by about 60%. In the presence of the uptake 1-blocker cocaine, facilitation was attenuated (increase by only 30%). This effect was abolished by the histamine H2 receptor antagonist cimetidine or the inhibitor of nitric oxide synthesis NG-nitro-(L)-(-)-arginine. When the preexposure time to 48/80 was reduced to 30 s, the facilitation was less pronounced (15%) and inverted to an inhibition in the presence of cocaine (plus idazoxan) by 17% and/or cimetidine (by about 30%). The resulting inhibition of noradrenaline efflux was attenuated by the serotonin 5-HT1/2 receptor antagonist methiothepin or the 5-HT2 antagonist ketanserin. Infusion of ovalbumin into hearts of not specifically sensitized, but sham treated rats (in vivo injection of a saline-alumina mixture 10-12 days before the in vitro experiment) did not affect histamine, serotonin or (basal and evoked) noradrenaline efflux. In hearts from rats that were previously sensitized by an injection of an ovalbumin-alumina adsorbate, ovalbumin induced a marked increase of histamine and serotonin efflux. When the infusion of the antigen started 30 s before SNS, evoked noradrenaline overflow was inhibited by about 60%. The inhibition was unaffected by histamine receptor antagonists, but attenuated by purinoceptor (suramin plus 1,3-dipropyl-8-cyclopentylxanthine), or serotonin receptor (methiothepin, rauwolscine or ketanserin) antagonists. When the preexposure time to ovalbumin was prolonged to 4 min before SNS, no significant change of stimulation-induced noradrenaline overflow was observed. Basal, immunologically and non-immunologically induced histamine and serotonin efflux were not significantly affected by SNS or any of the drugs tested. The results indicate a complex influence of various mediators released upon mast cell degranulation induced by two different stimuli on exocytotic noradrenaline release from rat heart. Depending on the stimulus and on the time interval between the start of the application of the mast cell degranulating agent and SNS, a histamine- and nitric oxide-mediated facilitation, or a serotonin- and purine-mediated inhibition prevails.
Asunto(s)
Degranulación de la Célula/efectos de los fármacos , Mastocitos/efectos de los fármacos , Ovalbúmina/toxicidad , Transmisión Sináptica/efectos de los fármacos , p-Metoxi-N-metilfenetilamina/toxicidad , Animales , Arginina/análogos & derivados , Arginina/farmacología , Sistema Nervioso Central/efectos de los fármacos , Sistema Nervioso Central/metabolismo , Cimetidina/farmacología , Cocaína/farmacología , Interacciones Farmacológicas , Liberación de Histamina/efectos de los fármacos , Técnicas In Vitro , Ketanserina/farmacología , Masculino , Mastocitos/fisiología , Metiotepina/farmacología , Miocardio/citología , Miocardio/metabolismo , Nitroarginina , Norepinefrina/metabolismo , Ovalbúmina/administración & dosificación , Perfusión , Ratas , Ratas Wistar , Serotonina/metabolismo , p-Metoxi-N-metilfenetilamina/administración & dosificaciónRESUMEN
Experiments were carried out in the isolated spleen of the rat to study in a lymphoid organ the influence of interleukins (ILs) on noradrenaline release. Spleens were perfused with Tyrode's solution and the overflow of endogenous noradrenaline was determined by HPLC with electrochemical detection. Perivascular electrical stimulation (4 or 10 Hz, 20-28 mA, 2 min) caused an increase in noradrenaline overflow and in perfusion pressure, both of which were markedly reduced by perfusion with Ca(2+)-free solution, abolished by tetrodotoxin, unaffected by hexamethonium, and subject to alpha 2-adrenoceptor- and muscarinic receptor-mediated modulation as shown by the effects of rauwolscine and methacholine. Human recombinant IL-1 beta and IL-2 and mouse recombinant IL-2 10 ng/ml failed to affect the evoked overflow of noradrenaline after an exposure time of 15 min. In contrast, human recombinant IL-1 beta and IL-2 0.1 ng/ml reduced the evoked overflow after exposure for 80 min; the inhibition tended to increase 30 min later despite washout. Murine recombinant IL-2 1.2 ng/ml caused no change after contact with the tissue for 80 min but there was an inhibition 30 min later after washout. Human recombinant IL-6 (0.1 ng/ml) caused no significant change. The inhibitory effect of low concentrations of IL-1 beta and IL-2 supports the idea that locally produced mediators of the immune system may affect neuronal function.
Asunto(s)
Interleucina-1/farmacología , Interleucina-2/farmacología , Interleucina-6/farmacología , Norepinefrina/metabolismo , Bazo/efectos de los fármacos , Animales , Interacciones Farmacológicas , Estimulación Eléctrica , Humanos , Soluciones Isotónicas , Masculino , Cloruro de Metacolina/farmacología , Ratones , Ratas , Ratas Wistar , Proteínas Recombinantes/farmacología , Bazo/metabolismo , Yohimbina/farmacologíaRESUMEN
Terminal nerve fibres of the autonomic nervous system closely approach mast cells in peripheral organs, and mutual influences between release of neurotransmitters or mast cell mediators may cause neuro-immunological interactions. We have studied the influence of mast cell degranulation on the release of endogenous noradrenaline and newly incorporated acetylcholine (such as 14C-choline/acetylcholine overflow) evoked by stimulation of extrinsic postganglionic sympathetic or preganglionic vagal nerves in the rat Langendorff heart perfused with Tyrode solution. Compound 48/80 perfused in normal hearts, or ovalbumin infused into hearts from rats sensitized to ovalbumin, enhanced the overflow of endogenous histamine and serotonin. Both stimuli increased the release of mediators to a similar extent and with fast kinetics. Maximum average concentrations in the perfusate of histamine were about 800 nmol/l, and of serotonin 40 nmol/l, in a sample collected within 4 min after mast cell degranulation. Stimulation of autonomic nerves did not affect basal histamine or serotonin overflow. Whereas basal overflows were unaffected, the stimulation-evoked releases of both noradrenaline and acetylcholine, were facilitated when compound 48/80 was perfused before and during nerve stimulation. The facilitation of noradrenaline overflow was more pronounced (by 60%) when compound 48/80-induced mediator overflow started 4 min before nerve stimulation as compared to 30 s (15%), and was reduced by cocaine (by 50%), and, in the presence of cocaine, abolished by cimetidine (but was unaffected by mepyramine and thioperamide) and NG-nitro-(L)-(-)-arginine. In the presence of cimetidine and cocaine, when the facilitatory components were abolished, the evoked noradrenaline overflow observed 30 s after the start of infusion of compound 48/80 was inhibited, and the inhibition was partly reduced by methiotepin and ketanserin. Ovalbumin infusion in hearts from sensitized animals caused an inhibition of evoked noradrenaline overflow sensitive to methiotepin and also partly to ketanserin, and no facilitation was observed. The facilitation (> 100%) of evoked overflow of acetylcholine observed at 4 min after the start of perfusion with compound 48/80 was partly reduced by thioperamide (but not mepyramine or cimetidine) and to a comparable extent either by tropisetron (3 mumol/l) alone or by tropisetron plus methiotepin. In conclusion, degranulation of immunological cells is followed by histamine and serotonin release in the rat heart and may affect the release of autonomic neurotransmitters in rather unusual ways, by i) an uptake1-dependent and ii) an H2-mediated facilitation which probably involves nitric oxide as a permissive mediator, and iii) a serotonergic inhibition, of noradrenaline release, and iv) an H3- and serotonergic facilitation of acetylcholine release.